The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide which is CE approved. Application data of CellCollector in China is not available now. The purpose of this clinical trial is to confirm the validation and safety of CellCollector in Chinese patients.
Study Type
INTERVENTIONAL
Enrollment
190
The 307th Hospital of Chinese People's Liberation Army
Beijing, Beijing Municipality, China
RECRUITINGValidation of CellCollector
CTC enumeration and detection rate in Chinese patients with metastasis breast cancer will be analyzed by using CellCollector.
Time frame: 6 month
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Number of participants with treatment-related adverse events and blood IgE level will be analyzed after CellCollector application.
Time frame: 6 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.